Skip to content

Vivani Medical VANI Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Amgen logo
AmgenAMGN
Prime Medicine logo
Prime MedicinePRME

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's common stock, shares authorized (in shares)?
Vivani Medical (VANI) reported common stock, shares authorized (in shares) of $300M in Q1 2026.
How has Vivani Medical's common stock, shares authorized (in shares) changed year-over-year?
Vivani Medical's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $300M to $300M.
What is the long-term trend for Vivani Medical's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Vivani Medical's common stock, shares authorized (in shares) has grown at a 298.1% compound annual growth rate (CAGR), from $300K to $300M.